CureME is at the forefront of participatory epidemiological, clinical and laboratory research into ME/CFS in the UK. Our research has focused on improving recognition, diagnosis and treatment of ME/CFS, leading to the opening of the UK’s first ME/CFS Biobank (UKMEB) – now open to researchers across the globe.
The UKMEB is the first ME/CFS-specific biobank in Europe, and one of the first in the world. It has collected over 30,000 aliquots of blood from patients with ME/CFS and multiple sclerosis (as well as healthy controls), using a rigorous and consistent set of scientific protocols.
CureME is committed to patient participation, and ensures that its research is always informed by and for the benefit of people with ME/CFS. We have contributed to highly significant research in immunology (including on NK and T cells and cytokine profiles), genetics, virology, clinical medicine, epidemiology and on the disabling effects of ME/CFS, and our Biobank has released samples to researchers in the UK, Europe, the Middle East and America.
The UKMEB was established by a consortium of charities and a private donor, and its continuing operation is funded through the generous support of the National Institutes of Health (USA) and the ME Association.
People suffer from ME/CFS
ME/CFS female to male ratio
More people suffer from ME/CFS than MS
Myalgic Encephalomyelitis (ME) is a long-term (chronic), fluctuating, neurological condition that causes symptoms affecting many body systems, most commonly the nervous and immune systems. ME affects an estimated 132,000 to 264,000 people in the UK, and around 17 million people worldwide. People with ME/CFS experience severe, persistent fatigue associated with post-exertional malaise (the body’s inability to recover after expending even small amounts of energy), and the disease has also been referred to as Chronic Fatigue Syndrome.